Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Mabwell Approved to Launch Biosimilar to Amgen's Osteoporosis Therapy in China

publication date: Apr 3, 2023

Shanghai Mabwell was approved to launch a denosumab biosimilar in China for osteoporosis in postmenopausal women at high risk of fracture. Mailishu, which was developed by Mabwell’s subsidiary T-mab, was shown to reduce the risk of vertebral, non-vertebral and hip fractures. Denosumab is a humanized mAb that inhibits the activator of nuclear factor kappa-B ligand (RANKL) to prevent development of osteoclasts, the cells that break down bone. The originator drug, Amgen’s Prolia/Xgeva was approved in the US in 2010, recording $5.6 billion in global revenues last year. More details....

Stock Symbol: (SHA: 688062)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital